Related Experiment Video

Updated: Nov 3, 2025

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.1K

Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma

Emanuele Vita1,2, Alessio Stefani1,2, Mariantonietta Di Salvatore1,2

  • 1Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Roma, Italy.

Journal of Clinical Medicine
|June 2, 2021
PubMed

Insights

Malignant pleural mesothelioma (MPM) treatment is evolving with immunotherapy and targeted drugs. Integrating these advances is crucial for complex patient care and improved outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Malignant pleural mesothelioma (MPM) is a rare cancer with limited treatment options and poor prognosis.
  • Immunotherapy shows promise, especially for non-epithelioid MPM.
  • Genomic sequencing offers potential for new targeted therapies.

Purpose of the Study:

  • To review the emerging treatment landscape for malignant pleural mesothelioma.
  • To highlight the role of immunotherapy and targeted drug development.
  • To emphasize the need for integrated treatment strategies.

Main Methods:

  • Review of current literature on MPM treatment.
  • Analysis of immunotherapy efficacy in MPM subtypes.
  • Exploration of genomic profiling for targeted therapy identification.

Main Results:

  • Immunotherapy is an effective treatment for MPM, particularly non-epithelioid types.
  • Comprehensive genomic sequencing identifies molecular vulnerabilities for targeted drug development.
  • The combination of these approaches complicates treatment algorithms.

Conclusions:

  • Novel immunotherapies and targeted drugs are transforming MPM treatment.
  • Developing clear treatment algorithms requires understanding complex molecular and immunological data.
  • Multidisciplinary collaboration is essential for optimal patient management in MPM.
Keywords:
immunotherapymalignant pleural mesotheliomatarget therapy

More Related Videos

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.0K
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.4K

Related Concept Videos

Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
400
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
358
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Pleura of the Lungs01:13

Pleura of the Lungs

The lungs are nestled in a cavity, shielded by the pleura. The pleura, a form of serous membrane, wraps around each lung. This membrane arrangement consists of two layers: the visceral and parietal pleurae. The visceral pleura lines the surface of the lungIn contrast, the parietal pleura is the outer layer and contacts to the thoracic wall, the mediastinum, and the diaphragm. The hilum is the point of connection between the visceral and parietal layers. The space between the parietal and...
4.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K